Race Oncology logo
RACRace Oncology
Trade RAC now
Race Oncology primary media

About Race Oncology

Race Oncology Limited (ASX:RAC) is an ASX-listed clinical stage biopharmaceutical company developing bisantrene, a novel anthracycline chemotherapeutic agent, for the treatment of a variety of cancers. Race Oncology's lead focus is on investigating the anti-cancer, cardio-protective and FTO properties of bisantrene in metastatic breast cancer, with a view to improving therapeutic outcomes and heart health for patients with cancer. Race Oncology is also pursuing increased anti-cancer / FTO benefits of bisantrene combined with current standard of care therapies in acute myeloid leukaemia (AML).

What is RAC known for?

Snapshot

Public AU
Ownership
2011
Year founded
12
Employees
New South Wales, Australia
Head office
1 of 545
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Australia

Products and/or services of Race Oncology

  • Development of bisantrene for cancer treatment: Bisantrene is a small molecule anthracycline that has shown promise in preclinical and clinical studies against various solid tumours, including breast, lung, and pancreatic cancer. Race Oncology is also evaluating bisantrene in combination with other cancer therapies.
  • Development of bispecific antibody platform: Race Oncology is developing a bispecific antibody platform that targets two different cancer antigens simultaneously. This platform has the potential to develop more effective and targeted cancer therapies.
  • Commitment to innovation and patient care: Race Oncology is committed to developing innovative cancer treatments that improve the lives of patients. The company is also committed to working with clinicians and researchers to bring its treatments to market as quickly as possible.

Race Oncology executive team

  • Dr. Peter Michael Smith Ph.D.Executive Chairman
  • Dr. Daniel TillettCEO, MD & Director
  • Mr. Brendan BrownChief Financial Officer
  • Dr. Sophia MoscovisVice President of Operations & Strategy
  • Dr. Jose L. Iglesias M.D.Chief Medical Officer
  • Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.